The Clinical Rationale for TIPS in Hepatocellular Carcinoma

Clinicians frequently encounter complex therapeutic dilemmas when managing advanced liver malignancy alongside severe cirrhosis. The implementation of TIPS in hepatocellular carcinoma represents a pivotal strategy to address portal hypertensive decompensation during systemic treatment. Historically, the combination of atezolizumab and bevacizumab transformed the standard first-line management of unresectable tumors. However, vascular endothelial growth factor inhibition significantly heightens the hazard of severe gastrointestinal bleeding. In patients with clinically significant portal hypertension, refractory ascites and bleeding gastroesophageal varices often cause premature treatment cessation. Consequently, maintaining hepatic reserve while delivering effective systemic antineoplastic therapy poses a continuous clinical hurdle. A transjugular intrahepatic portosystemic shunt rapidly decompresses the portal venous system. Thus, it directly mitigates the catastrophic sequelae of elevated sinusoidal pressure. Despite these physiological advantages, oncologists have historically approached shunting with caution due to concerns regarding hepatic encephalopathy and tumor disruption. Therefore, structured clinical evidence is vital to clarify whether mechanical portal decompression safely preserves liver function during dual immunotherapy and anti-angiogenic regimens. Emerging real-world frameworks now seek to establish this vital equilibrium.

Overview of the NISTIPS TRITICC-4 Study Design

To resolve these longstanding clinical uncertainties, investigators launched the prospective NISTIPS TRITICC-4 study across twenty-five specialized academic centers in Germany. This prospective, non-interventional cohort study plans to recruit 350 adult patients presenting with cirrhosis and unresectable or metastatic liver cancer. Crucially, all enrolled individuals receive standard first-line therapy comprising atezolizumab and bevacizumab. The study design stratifies participants into two cohorts based on standard clinical practice decisions. Specifically, the first cohort includes patients who have a functioning shunt in situ alongside systemic therapy. Conversely, the second cohort receives atezolizumab plus bevacizumab alone without portosystemic shunting. Because clinicians determine shunt placement based on routine clinical indications rather than artificial randomization, the study captures authentic therapeutic trajectories. Furthermore, investigators employ robust propensity score matching to balance baseline prognostic factors and limit confounding by indication. This design enables a rigorous comparison of clinical trajectories between shunted and non-shunted cohorts. As a result, the protocol provides an indispensable framework to assess real-world procedural outcomes in an otherwise excluded high-risk population.

Evaluating Time to Deterioration of Liver Function

Preserving baseline hepatic reserve remains paramount because functional hepatic decline frequently terminates antineoplastic therapy prematurely. Therefore, the NISTIPS TRITICC-4 protocol designates time to deterioration of liver function as its primary efficacy endpoint. The investigators define this endpoint as a persistent worsening of key hepatic laboratory parameters lasting for at least four consecutive weeks. In advanced cirrhosis, vascular decompensation often precedes oncologic progression. Consequently, preventing bilirubin elevation, worsening coagulopathy, or intractable fluid retention directly prolongs the therapeutic window for systemic immunotherapy. By reducing portal venous pressure gradients, shunting can theoretically stabilize hepatic microcirculation and suppress recurrent ascites formation. Secondary endpoints further enrich this inquiry by analyzing overall survival, progression-free survival, objective response rates, and time on treatment. Additionally, researchers will evaluate the time to appearance of new extrahepatic lesions or death. If shunted patients achieve longer functional stability, they may tolerate prolonged exposure to checkpoint inhibitors. Ultimately, maintaining stable hepatic function enables patients to reap the cumulative benefits of contemporary immunotherapy regimens.

Addressing Safety Concerns and Hemorrhagic Risk

The clinical administration of bevacizumab carries an acknowledged risk of serious gastrointestinal hemorrhage, particularly in portal hypertension. Endoscopic screening and proactive variceal eradication represent universal standard-of-care requirements before initiating anti-angiogenic therapy. However, endoscopic band ligation primarily treats visible varices without lowering the underlying sinusoidal hydrostatic pressure. In contrast, an intrahepatic portosystemic stent permanently decompresses the entire splanchnic circulation, substantially diminishing collateral wall tension. The trial meticulously tracks safety outcomes, focusing specifically on variceal bleeding episodes, procedure-related morbidity, and hepatic decompensation events. Furthermore, the development of post-shunt hepatic encephalopathy requires vigilant prospective monitoring. Clinicians frequently worry that diversion of portal blood flow might induce hyperammonemia or impair drug metabolism. Nevertheless, modern controlled-expansion covered stents allow precise caliber adjustments to prevent excessive systemic shunting. Thus, the NISTIPS TRITICC-4 trial will delineate whether the mechanical protection against fatal bleeding outweighs the risk of secondary neurocognitive side effects. These safety data will provide critical clarity for multidisciplinary tumor boards.

Translating Real-World Findings into Multidisciplinary Practice

The intersection of advanced portal hypertension and systemic cancer therapy requires close collaboration across gastroenterology, interventional radiology, and oncology. In clinical practice, patients with decompensated cirrhosis or severe portal hypertension frequently face exclusion from registration clinical trials. Consequently, clinicians lack definitive guidance when deciding whether a patient with existing shunts can safely initiate immunotherapy. The prospective data generated by the NISTIPS TRITICC-4 study will bridge this persistent evidence gap. Moreover, these insights will assist hepatologists in selecting appropriate candidates for prophylactic portal decompression prior to initiating targeted anti-angiogenic combinations. Shunt patency, baseline liver score, and systemic tumor burden must guide every individualized treatment decision. In developing healthcare ecosystems, where patients often present at advanced stages with established variceal pathology, practical management algorithms remain vital. Ultimately, integrating proactive portal pressure reduction into comprehensive cancer pathways may transform clinical outcomes. By preventing life-threatening gastrointestinal decompensation, clinicians can maximize antineoplastic efficacy while preserving vital organ function.

Frequently Asked Questions

Why is portal hypertension particularly hazardous during atezolizumab plus bevacizumab therapy?

Portal hypertension creates high-pressure collateral vessels, including esophageal and gastric varices, which are prone to rupture. When clinicians administer bevacizumab, its potent inhibition of vascular endothelial growth factor impairs normal endothelial repair and significantly amplifies bleeding tendencies. Consequently, an unexpected variceal rupture can precipitate catastrophic, life-threatening gastrointestinal hemorrhage. This severe complication often forces permanent discontinuation of life-extending antineoplastic therapy, highlighting why clinicians must aggressively manage portal pressures prior to treatment initiation.

How does TIPS potentially benefit patients receiving systemic therapy for hepatocellular carcinoma?

A transjugular intrahepatic portosystemic shunt establishes an artificial low-resistance conduit between the portal and systemic venous systems. By directly decompressing portal hypertension, the shunt alleviates refractory ascites and substantially reduces the hydrostatic tension across vulnerable gastroesophageal varices. Consequently, patients experience fewer decompensation episodes and reduced hemorrhagic events during systemic treatment. This hemodynamic stabilization preserves functional liver reserve, thereby allowing patients to remain on first-line atezolizumab plus bevacizumab for a significantly longer duration.

What are the primary clinical risks of performing TIPS in advanced cancer?

The primary concern associated with shunt creation is the development or exacerbation of hepatic encephalopathy due to diversion of neurotoxins past hepatic clearance. Additionally, acute diversion of portal blood flow can compromise hepatic perfusion, potentially precipitating ischemic liver injury in borderline patients. Clinicians must also consider procedural challenges, including inadvertent puncture of intrahepatic tumor nodules or stent thrombosis. Careful patient selection and utilization of modern caliber-controlled stent grafts remain essential to minimize these clinical hazards.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding clinical decisions, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Angendohr C et al. Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092). Future Oncol. 2026 Oct 20. doi: 10.1080/14796694.2026.2748246. PMID: 42902603.

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.

de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974.